Inhibitors of Influenza Virus Polymerase Acidic (PA) Endonuclease: Contemporary Developments and Perspectives

Journal of Medicinal Chemistry

Volumn 60, Issue 9, 2017, Pages 3533-3551

  Ju, Han ^a   Zhang, Jian ^a   Huang, Boshi ^a   Kang, Dongwei ^a   Huang, Bing ^b   Liu, Xinyong ^a   Zhan, Peng ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PEANUT RESEARCH INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDROXYBENZOIC ACID; ANTIVIRUS AGENT; CATECHOL DERIVATIVE; DIKETO ACID DERIVATIVE; ENDONUCLEASE; ESTERASE INHIBITOR; FLUTIMIDE DERIVATIVE; HETEROCYCLIC COMPOUND; POLYMERASE ACIDIC ENDONUCLEASE; POLYMERASE ACIDIC ENDONUCLEASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS ENZYME; ENZYME INHIBITOR;

ANTAGONIST POTENCY; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME STRUCTURE; HYDROXYLATION; INFLUENZA; INFLUENZA VIRUS; MEDICINAL CHEMISTRY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DOG; ENZYMOLOGY; INFLUENZA A VIRUS (H1N1); MDCK CELL LINE; METABOLISM; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIVIRAL AGENTS; CRYSTALLOGRAPHY, X-RAY; DOGS; ENDONUCLEASES; ENZYME INHIBITORS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MADIN DARBY CANINE KIDNEY CELLS;

EID: 85018868773     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b01227     Document Type: Article

References (109)

1. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD) Website; October 31, 2016. https://www.cdc.gov/flu/about/disease/.
2. Chowell, G.; Bertozzi, S. M.; Colchero, M. A.; Lopez-Gatell, H.; Alpuche-Aranda, C.; Hernandez, M.; Miller, M. A. Severe respiratory disease concurrent with the circulation of H1N1 influenza N. Engl. J. Med. 2009, 361, 674-679 10.1056/NEJMoa0904023
3. Li, T. C.; Chan, M. C.; Lee, N. Clinical implications of antiviral resistance in influenza Viruses 2015, 7, 4929-4944 10.3390/v7092850
4. Yen, H. L. Current and novel antiviral strategies for influenza infection Curr. Opin. Virol. 2016, 18, 126-134 10.1016/j.coviro.2016.05.004
5. Du, J.; Cross, T. A.; Zhou, H. X. Recent progress in structure-based anti-influenza drug design Drug Discovery Today 2012, 17, 1111-1120 10.1016/j.drudis.2012.06.002
6. Nichol, K. L.; Treanor, J. J. Vaccines for seasonal and pandemic influenza J. Infect. Dis. 2006, 194 ( Suppl. 2 ) S111-S118 10.1086/507544
7. Subbarao, K.; Joseph, T. Scientific barriers to developing vaccines against avian influenza viruses Nat. Rev. Immunol. 2007, 7, 267-278 10.1038/nri2054
8. Das, K.; Aramini, J. M.; Ma, L. C.; Krug, R. M.; Arnold, E. Structures of influenza A proteins and insights into antiviral drug targets Nat. Struct. Mol. Biol. 2010, 17, 530-538 10.1038/nsmb.1779
9. Davies, W. L.; Grunert, R. R.; Haff, R. F.; Mcgahen, J. W.; Neumayer, E. M.; Paulshock, M.; Watts, J. C.; Wood, T. R.; Hermann, E. C.; Hoffmann, C. E. Antiviral activity of 1-adamantanamine (amantadine) Science 1964, 144, 862-863 10.1126/science.144.3620.862
10. Dunning, J.; Baillie, J. K.; Cao, B.; Hayden, F. G. International severe acute respiratory and emerging infection consortium (ISARIC). antiviral combinations for severe influenza Lancet Infect. Dis. 2014, 14, 1259-1270 10.1016/S1473-3099(14)70821-7
11. Smee, D. F.; Sidwell, R. W. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza Expert Opin. Invest. Drugs 2002, 11, 859-869 10.1517/13543784.11.6.859
12. Cheng, C. K.; Tsai, C. H.; Shie, J. J.; Fang, J. M. From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs? Future Med. Chem. 2014, 6, 757-774 10.4155/fmc.14.30
13. Furuta, Y.; Gowen, B. B.; Takahashi, K.; Shiraki, K.; Smee, D. F.; Barnard, D. L. Favipiravir (T-705), a novel viral RNA polymerase inhibitor Antiviral Res. 2013, 100, 446-454 10.1016/j.antiviral.2013.09.015
14. Bright, R. A.; Shay, D. K.; Shu, B.; Cox, N. J.; Klimov, A. I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States JAMA 2006, 295, 891-894 10.1001/jama.295.8.joc60020
15. Amarelle, L.; Lecuona, E.; Sznajder, J. I. Anti-influenza treatment: Drugs currently used and under development Arch. Bronconeumol. 2017, 53, 19-26 10.1016/j.arbr.2016.11.020
16. Rey-Carrizo, M.; Barniol-Xicota, M.; Ma, C.; Frigolé-Vivas, M.; Torres, E.; Naesens, L.; Llabrés, S.; Juárez-Jiménez, J.; Luque, F. J.; DeGrado, W. F.; Lamb, R. A.; Pinto, L. H.; Vázquez, S. Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus J. Med. Chem. 2014, 57, 5738-5747 10.1021/jm5005804
17. Collins, P. J.; Haire, L. F.; Lin, Y. P.; Liu, J.; Russell, R. J.; Walker, P. A.; Skehel, J. J.; Martin, S. R.; Hay, A. J.; Gamblin, S. J. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants Nature 2008, 453, 1258-1261 10.1038/nature06956
18. Moscona, A. Global transmission of oseltamivir-resistant influenza N. Engl. J. Med. 2009, 360, 953-956 10.1056/NEJMp0900648
19. Stiver, G. The treatment of influenza with antiviral drugs Can. Med. Assoc. J. 2003, 168, 49-56
20. U.S. Food and Drug Administration. Tamiflu pediatric adverse events: questions and answers; December 07, 2015. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107840.htm.
21. Naesens, L.; Stevaert, A.; Vanderlinden, E. Antiviral therapies on the horizon for influenza Curr. Opin. Pharmacol. 2016, 30, 106-115 10.1016/j.coph.2016.08.003
22. Stevaert, A.; Naesens, L. The influenza virus polymerase complex: an update on its structure, functions, and significance for antiviral drug design Med. Res. Rev. 2016, 36, 1127-1173 10.1002/med.21401
23. Boivin, S.; Cusack, S.; Ruigrok, R. W.; Hart, D. J. Influenza A virus polymerase: structural insights into replication and host adaptation mechanisms J. Biol. Chem. 2010, 285, 28411-28417 10.1074/jbc.R110.117531
24. Pflug, A.; Guilligay, D.; Reich, S.; Cusack, S. Structure of influenza A polymerase bound to the viral RNA promoter Nature 2014, 516, 355-360 10.1038/nature14008
25. Dias, A.; Bouvier, D.; Crépin, T.; McCarthy, A. A.; Hart, D. J.; Baudin, F.; Cusack, S.; Ruigrok, R. W. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit Nature 2009, 458, 914-918 10.1038/nature07745
26. Reich, S.; Guilligay, D.; Pflug, A.; Malet, H.; Berger, I.; Crépin, T.; Hart, D.; Lunardi, T.; Nanao, M.; Ruigrok, R. W.; Cusack, S. Structural insight into cap-snatching and RNA synthesis by influenza polymerase Nature 2014, 516, 361-366 10.1038/nature14009
27. He, X.; Zhou, J.; Bartlam, M.; Zhang, R.; Ma, J.; Lou, Z.; Li, X.; Li, J.; Joachimiak, A.; Zeng, Z.; Ge, R.; Rao, Z.; Liu, Y. Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian influenza H5N1 virus Nature 2008, 454, 1123-1126 10.1038/nature07120
28. Yuan, P.; Bartlam, M.; Lou, Z.; Chen, S.; Zhou, J.; He, X.; Lv, Z.; Ge, R.; Li, X.; Deng, T.; Fodor, E.; Rao, Z.; Liu, Y. Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site Nature 2009, 458, 909-913 10.1038/nature07720
29. Monod, A.; Swale, C.; Tarus, B.; Tissot, A.; Delmas, B.; Ruigrok, R. W.; Crépin, T.; Slama-Schwok, A. Learning from structure-based drug design and new antivirals targeting the ribonucleoprotein complex for the treatment of influenza Expert Opin. Drug Discovery 2015, 10, 345-371 10.1517/17460441.2015.1019859
30. Song, M. S.; Kumar, G.; Shadrick, W. R.; Zhou, W.; Jeevan, T.; Li, Z.; Slavish, P. J.; Fabrizio, T. P.; Yoon, S. W.; Webb, T. R.; Webby, R. J.; White, S. W. Identification and characterization of influenza variants resistant to a viral endonuclease inhibitor Proc. Natl. Acad. Sci. U. S. A. 2016, 113, 3669-3674 10.1073/pnas.1519772113
31. Tefsen, B.; Lu, G.; Zhu, Y.; Haywood, J.; Zhao, L.; Deng, T.; Qi, J.; Gao, G. F. The N-terminal domain of PA from bat-derived influenza-like virus H17N10 has endonuclease activity J. Virol. 2014, 88, 1935-1941 10.1128/JVI.03270-13
32. DuBois, R. M.; Slavish, P. J.; Baughman, B. M.; Yun, M. K.; Bao, J.; Webby, R. J.; Webb, T. R.; White, S. W. Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease PLoS Pathog. 2012, 8, e1002830 10.1371/journal.ppat.1002830
33. Zhao, C.; Lou, Z.; Guo, Y.; Ma, M.; Chen, Y.; Liang, S.; Zhang, L.; Chen, S.; Li, X.; Liu, Y.; Bartlam, M.; Rao, Z. Nucleoside monophosphate complex structures of the endonuclease domain from the influenza virus polymerase PA subunit reveal the substrate binding site inside the catalytic center J. Virol. 2009, 83, 9024-9030 10.1128/JVI.00911-09
34. Kotlarek, D.; Worch, R. New insight into metal ion-driven catalysis of nucleic acids by influenza PA-Nter PLoS One 2016, 11, e0156972 10.1371/journal.pone.0156972
35. Kowalinski, E.; Zubieta, C.; Wolkerstorfer, A.; Szolar, O. H.; Ruigrok, R. W.; Cusack, S. Structural analysis of specific metal chelating inhibitor binding to the endonuclease domain of influenza pH1N1 (2009) polymerase PLoS Pathog. 2012, 8, e1002831 10.1371/journal.ppat.1002831
36. De Clercq, E.; Neyts, J. Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention Trends Pharmacol. Sci. 2007, 28, 280-285 10.1016/j.tips.2007.04.005
37. Liu, Y.; Lou, Z.; Bartlam, M.; Rao, Z. Structure-function studies of the influenza virus RNA polymerase PA subunit Sci. China, Ser. C: Life Sci. 2009, 52, 450-458 10.1007/s11427-009-0060-1
38. Stevaert, A.; Nurra, S.; Pala, N.; Carcelli, M.; Rogolino, D.; Shepard, C.; Domaoal, R. A.; Kim, B.; Alfonso-Prieto, M.; Marras, S. A.; Sechi, M.; Naesens, L. An integrated biological approach to guide the development of metal-chelating inhibitors of influenza virus PA endonuclease Mol. Pharmacol. 2015, 87, 323-337 10.1124/mol.114.095588
39. Tomassini, J.; Selnick, H.; Davies, M. E.; Armstrong, M. E.; Baldwin, J.; Bourgeois, M.; Hastings, J.; Hazuda, D.; Lewis, J.; McClements, W.; Ponticello, G.; Radzilowski, E.; Smith, G.; Tebben, A.; Wolfe’, A. Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds Antimicrob. Agents Chemother. 1994, 38, 2827-2837 10.1128/AAC.38.12.2827
40. Song, Y.; Chen, W.; Kang, D.; Zhang, Q.; Zhan, P.; Liu, X. "Old friends in new guise": exploiting privileged structures for scaffold re-evolution/refining Comb. Chem. High Throughput Screening 2014, 17, 536-553 10.2174/1386207317666140122101631
41. Hastings, J. C.; Selnick, H.; Wolanski, B.; Tomassini, J. E. Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors Antimicrob. Agents Chemother. 1996, 40, 1304-1307
42. Ishikawa, Y.; Fujii, S. Binding mode prediction and inhibitor design of anti-influenza virus diketo acids targeting metalloenzyme RNA polymerase by molecular docking Bioinformation 2011, 6, 221-225 10.6026/97320630006221
43. Stevaert, A.; Dallocchio, R.; Dessì, A.; Pala, N.; Rogolino, D.; Sechi, M.; Naesens, L. Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease J. Virol. 2013, 87, 10524-10538 10.1128/JVI.00832-13
44. Fudo, S.; Yamamoto, N.; Nukaga, M.; Odagiri, T.; Tashiro, M.; Hoshino, T. Two distinctive binding modes of endonuclease inhibitors to the N-terminal region of influenza virus polymerase acidic subunit Biochemistry 2016, 55, 2646-2660 10.1021/acs.biochem.5b01087
45. Chen, E.; Swift, R. V.; Alderson, N.; Feher, V. A.; Feng, G. S.; Amaro, R. E. Computation-guided discovery of influenza endonuclease inhibitors ACS Med. Chem. Lett. 2014, 5, 61-64 10.1021/ml4003474
46. Tomassini, J. E.; Davies, M. E.; Hastings, J. C.; Lingham, R.; Mojena, M.; Raghoobar, S. L.; Singh, S. B.; Tkacz, J. S.; Goetz, M. A. A novel antiviral agent which inhibits the endonuclease of influenza viruses Antimicrob. Agents Chemother. 1996, 40, 1189-1193
47. Singh, S. B.; Tomassini, J. E. Synthesis of natural flutimide and analogous fully substituted pyrazine-2,6-diones, endonuclease inhibitors of influenza virus J. Org. Chem. 2001, 66, 5504-5516 10.1021/jo015665d
48. Zoidis, G.; Giannakopoulou, E.; Stevaert, A.; Frakolaki, E.; Myrianthopoulos, V.; Fytas, G.; Mavromara, P.; Mikros, E.; Bartenschlager, R.; Vassilaki, N.; Naesens, L. Novel indole-flutimide heterocycles with activity against influenza PA endonuclease and hepatitis C virus MedChemComm 2016, 7, 447-456 10.1039/C5MD00439J
49. Parkes, K. E.; Ermert, P.; Fässler, J.; Ives, J.; Martin, J. A.; Merrett, J. H.; Obrecht, D.; Williams, G.; Klumpp, K. Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors J. Med. Chem. 2003, 46, 1153-1164 10.1021/jm020334u
50. Sagong, H. Y.; Parhi, A.; Bauman, J. D.; Patel, D.; Vijayan, R. S.; Das, K.; Arnold, E.; LaVoie, E. J. 3-Hydroxyquinolin-2(1H)-ones as inhibitors of influenza A endonuclease ACS Med. Chem. Lett. 2013, 4, 547-550 10.1021/ml4001112
51. Sagong, H. Y.; Bauman, J. D.; Patel, D.; Das, K.; Arnold, E.; LaVoie, E. J. Phenyl substituted 4-hydroxypyridazin-3(2H)-ones and 5-hydroxypyrimidin-4(3H)-ones: inhibitors of influenza A endonuclease J. Med. Chem. 2014, 57, 8086-8098 10.1021/jm500958x
52. Patel, D.; Bauman, J. D.; Arnold, E. Advantages of crystallographic fragment screening: functional and mechanistic insights from a powerful platform for efficient drug discovery Prog. Biophys. Mol. Biol. 2014, 116, 92-100 10.1016/j.pbiomolbio.2014.08.004
53. Davies, T. G.; Tickle, I. J. Fragment screening using X-ray crystallography Top. Curr. Chem. 2011, 317, 33-59 10.1007/128_2011_179
54. Jhoti, H.; Cleasby, A.; Verdonk, M.; Williams, G. Fragment-based screening using X-ray crystallography and NMR spectroscopy Curr. Opin. Chem. Biol. 2007, 11, 485-493 10.1016/j.cbpa.2007.07.010
55. Parhi, A. K.; Xiang, A.; Bauman, J. D.; Patel, D.; Vijayan, R. S.; Das, K.; Arnold, E.; Lavoie, E. J. Phenyl substituted 3-hydroxypyridin-2(1H)-ones: inhibitors of influenza A endonuclease Bioorg. Med. Chem. 2013, 21, 6435-6446 10.1016/j.bmc.2013.08.053
56. Bauman, J. D.; Patel, D.; Baker, S. F.; Vijayan, R. S.; Xiang, A.; Parhi, A. K.; Martínez-Sobrido, L.; LaVoie, E. J.; Das, K.; Arnold, E. Crystallographic fragment screening and structure-based optimization yields a new class of influenza endonuclease inhibitors ACS Chem. Biol. 2013, 8, 2501-2508 10.1021/cb400400j
57. Huang, B.; Kang, D.; Zhan, P.; Liu, X. Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities Expert Opin. Drug Discovery 2015, 10, 1271-1281 10.1517/17460441.2015.1083007
58. Credille, C. V.; Chen, Y.; Cohen, S. M. Fragment-based identification of influenza endonuclease inhibitors J. Med. Chem. 2016, 59, 6444-6454 10.1021/acs.jmedchem.6b00628
59. Miyagawa, M.; Akiyama, T.; Mikamiyama-Iwata, M.; Hattori, K.; Kurihara, N.; Taoda, Y.; Takahashi-Kageyama, C.; Kurose, N.; Mikamiyama, H.; Suzuki, N.; Takaya, K.; Tomita, K.; Matsuo, K.; Morimoto, K.; Yoshida, R.; Shishido, T.; Yoshinaga, T.; Sato, A.; Kawai, M. Discovery of novel 5-hydroxy-4-pyridone-3-carboxy acids as potent inhibitors of influenza cap-dependent endonuclease Bioorg. Med. Chem. Lett. 2016, 26, 4739-4742 10.1016/j.bmcl.2016.08.038
60. Pala, N.; Stevaert, A.; Dallocchio, R.; Dessì, A.; Rogolino, D.; Carcelli, M.; Sanna, V.; Sechi, M.; Naesens, L. Virtual screening and biological validation of novel influenza virus PA endonuclease inhibitors ACS Med. Chem. Lett. 2015, 6, 866-871 10.1021/acsmedchemlett.5b00109
61. Iwai, Y.; Takahashi, H.; Hatakeyama, D.; Motoshima, K.; Ishikawa, M.; Sugita, K.; Hashimoto, Y.; Harada, Y.; Itamura, S.; Odagiri, T.; Tashiro, M.; Sei, Y.; Yamaguchi, K.; Kuzuhara, T. Anti-influenza activity of phenethylphenylphthalimide analogs derived from thalidomide Bioorg. Med. Chem. 2010, 18, 5379-5390 10.1016/j.bmc.2010.05.035
62. Song, J. M.; Lee, K. H.; Seong, B. L. Antiviral effect of catechins in green tea on influenza virus Antiviral Res. 2005, 68, 66-74 10.1016/j.antiviral.2005.06.010
63. Kuzuhara, T.; Iwai, Y.; Takahashi, H.; Hatakeyama, D.; Echigo, N. Green tea catechins inhibit the endonuclease activity of influenza A virus RNA polymerase PLoS Curr. 2009, 1, RRN1052 10.1371/currents.RRN1052
64. Mori, S.; Miyake, S.; Kobe, T.; Nakaya, T.; Fuller, S. D.; Kato, N.; Kaihatsu, K. Enhanced anti-influenza A virus activity of (−)-epigallocatechin-3-O-gallate fatty acid monoester derivatives: effect of alkyl chain length Bioorg. Med. Chem. Lett. 2008, 18, 4249-4252 10.1016/j.bmcl.2008.02.020
65. Rogolino, D.; Bacchi, A.; De Luca, L.; Rispoli, G.; Sechi, M.; Stevaert, A.; Naesens, L.; Carcelli, M. Investigation of the salicylaldehyde thiosemicarbazone scaffold for inhibition of influenza virus PA endonuclease JBIC, J. Biol. Inorg. Chem. 2015, 20, 1109-1121 10.1007/s00775-015-1292-0
66. Iwai, Y.; Murakami, K.; Gomi, Y.; Hashimoto, T.; Asakawa, Y.; Okuno, Y.; Ishikawa, T.; Hatakeyama, D.; Echigo, N.; Kuzuhara, T. Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts PLoS One 2011, 6, e19825 10.1371/journal.pone.0019825
67. Fudo, S.; Yamamoto, N.; Nukaga, M.; Odagiri, T.; Tashiro, M.; Neya, S.; Hoshino, T. Structural and computational study on inhibitory compounds for endonuclease activity of influenza virus polymerase Bioorg. Med. Chem. 2015, 23, 5466-5475 10.1016/j.bmc.2015.07.046
68. Carcelli, M.; Rogolino, D.; Gatti, A.; De Luca, L.; Sechi, M.; Kumar, G.; White, S. W.; Stevaert, A.; Naesens, L. N-acylhydrazone inhibitors of influenza virus PA endonuclease with versatile metal binding modes Sci. Rep. 2016, 6, 31500 10.1038/srep31500
69. Lima, L. M.; Barreiro, E. J. Bioisosterism: a useful strategy for molecular modification and drug design Curr. Med. Chem. 2005, 12, 23-49 10.2174/0929867053363540
70. Doan, L.; Handa, B.; Roberts, N. A.; Klumpp, K. Metal ion catalysis of RNA cleavage by the influenza virus endonuclease Biochemistry 1999, 38, 5612-5619 10.1021/bi9828932
71. Carcelli, M.; Rogolino, D.; Bacchi, A.; Rispoli, G.; Fisicaro, E.; Compari, C.; Sechi, M.; Stevaert, A.; Naesens, L. Metal-chelating 2-hydroxyphenyl amide pharmacophore for inhibition of influenza virus endonuclease Mol. Pharmaceutics 2014, 11, 304-316 10.1021/mp400482a
72. Jones, J. C.; Marathe, B. M.; Lerner, C.; Kreis, L.; Gasser, R.; Pascua, P. N.; Najera, I.; Govorkova, E. A. A novel endonuclease inhibitor exhibits broad-spectrum anti-influenza activity in vitro Antimicrob. Agents Chemother. 2016, 60, 5504-5514 10.1128/AAC.00888-16
73. Yamada, K.; Koyama, H.; Hagiwara, K.; Ueda, A.; Sasaki, Y.; Kanesashi, S. N.; Ueno, R.; Nakamura, H. K.; Kuwata, K.; Shimizu, K.; Suzuki, M.; Aida, Y. Identification of a novel compound with antiviral activity against influenza A virus depending on PA subunit of viral RNA polymerase Microbes Infect. 2012, 14, 740-747 10.1016/j.micinf.2012.02.012
74. Yuan, S.; Chu, H.; Singh, K.; Zhao, H.; Zhang, K.; Kao, R. Y.; Chow, B.; Zhou, J.; Zheng, B. J. A novel small-molecule inhibitor of influenza A virus acts by suppressing PA endonuclease activity of the viral polymerase Sci. Rep. 2016, 6, 22880 10.1038/srep22880
75. Kang, D.; Song, Y.; Chen, W.; Zhan, P.; Liu, X. "Old dogs with new tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets Mol. BioSyst. 2014, 10, 1998-2022 10.1039/C4MB00147H
76. 1st Half of Fiscal 2015. Financial Results; October 30, 2015. http://www.shionogi.co.jp/en/ir/pdf/e_p151030.pdf.
77. https://clinicaltrials.gov/ct2/show/NCT02588521. ClinicalTrials.gov processed this record on January 19, 2017.
78. Jacobsen, J. A.; Fullagar, J. L.; Miller, M. T.; Cohen, S. M. Identifying chelators for metalloprotein inhibitors using a fragment-based approach J. Med. Chem. 2011, 54, 591-602 10.1021/jm101266s
79. Wang, X.; Huang, B.; Liu, X.; Zhan, P. Discovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries Drug Discovery Today 2016, 21, 118-132 10.1016/j.drudis.2015.08.004
80. Franzini, R. M.; Neri, D.; Scheuermann, J. DNA-encoded chemical libraries: advancing beyond conventional small-molecule libraries Acc. Chem. Res. 2014, 47, 1247-1255 10.1021/ar400284t
81. Djuric, S. W.; Meanwell, N. A. Journal of medicinal chemistry, Technological advances: highlights 2015-2016 J. Med. Chem. 2017, 60, 1-3 10.1021/acs.jmedchem.6b01600
82. Chen, Y. C. Beware of docking! Trends Pharmacol. Sci. 2015, 36, 78-95 10.1016/j.tips.2014.12.001
83. Martin, D. P.; Blachly, P. G.; McCammon, J. A.; Cohen, S. M. Exploring the influence of the protein environment on metal-binding pharmacophores J. Med. Chem. 2014, 57, 7126-7135 10.1021/jm500984b
84. Pottel, J.; Therrien, E.; Gleason, J. L.; Moitessier, N. Docking ligands into flexible and solvated macromolecules. 6. Development and application to the docking of HDACs and other zinc metalloenzymes inhibitors J. Chem. Inf. Model. 2014, 54, 254-265 10.1021/ci400550m
85. Irwin, J. J.; Raushel, F. M.; Shoichet, B. K. Virtual screening against metalloenzymes for inhibitors and substrates Biochemistry 2005, 44, 12316-12328 10.1021/bi050801k
86. Xiao, S.; Klein, M. L.; LeBard, D. N.; Levine, B. G.; Liang, H.; MacDermaid, C. M.; Alfonso-Prieto, M. Magnesium-dependent RNA binding to the PA endonuclease domain of the avian influenza polymerase J. Phys. Chem. B 2014, 118, 873-889 10.1021/jp408383g
87. Vidic, J.; Noiray, M.; Bagchi, A.; Slama-Schwok, A. Identification of a novel complex between the nucleoprotein and PA(1-27) of influenza A virus polymerase Biochemistry 2016, 55, 4259-4262 10.1021/acs.biochem.6b00514
88. Geppert, H.; Vogt, M.; Bajorath, J. Current trends in ligand-based virtual screening: Molecular representations, data mining methods, new application areas, and performance evaluation J. Chem. Inf. Model. 2010, 50, 205-216 10.1021/ci900419k
89. Dayam, R.; Sanchez, T.; Clement, O.; Shoemaker, R.; Sei, S.; Neamati, N. Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors J. Med. Chem. 2005, 48, 111-120 10.1021/jm0496077
90. Dayam, R.; Sanchez, T.; Neamati, N. Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase J. Med. Chem. 2005, 48, 8009-8015 10.1021/jm050837a
91. Barreca, M. L.; Ferro, S.; Rao, A.; De Luca, L.; Zappalà, M.; Monforte, A. M.; Debyser, Z.; Witvrouw, M.; Chimirri, A. Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors J. Med. Chem. 2005, 48, 7084-7088 10.1021/jm050549e
92. Klumpp, K.; Hang, J. Q.; Rajendran, S.; Yang, Y.; Derosier, A.; Wong, Kai.; In, P.; Overton, H.; Parkes, K. E.; Cammack, N.; Martin, J. A. Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors Nucleic Acids Res. 2003, 31, 6852-6859 10.1093/nar/gkg881
93. Fan, X.; Zhang, F. H.; Al-Safi, R. I.; Zeng, L. F.; Shabaik, Y.; Debnath, B.; Sanchez, T. W.; Odde, S.; Neamati, N.; Long, Y. Q. Design of HIV-1 integrase inhibitors targeting the catalytic domain as well as its interaction with LEDGF/p75: A scaffold hopping approach using salicylate and catechol groups Bioorg. Med. Chem. 2011, 19, 4935-4952 10.1016/j.bmc.2011.06.058
94. Kirschberg, T. A.; Balakrishnan, M.; Squires, N. H.; Barnes, T.; Brendza, K. M.; Chen, X.; Eisenberg, E. J.; Jin, W.; Kutty, N.; Leavitt, S.; Liclican, A.; Liu, Q.; Liu, X.; Mak, J.; Perry, J. K.; Wang, M.; Watkins, W. J.; Lansdon, E. B. RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information J. Med. Chem. 2009, 52, 5781-5784 10.1021/jm900597q
95. Reguera, J.; Weber, F.; Cusack, S. Bunyaviridae RNA polymerases (L-protein) have an N-terminal, influenza-like endonuclease domain, essential for viral cap-dependent transcription PLoS Pathog. 2010, 6, e1001101 10.1371/journal.ppat.1001101
96. Krieger, I. V.; Freundlich, J. S.; Gawandi, V. B.; Roberts, J. P.; Gawandi, V. B.; Sun, Q.; Owen, J. L.; Fraile, M. T.; Huss, S. I.; Lavandera, J. L.; Ioerger, T. R.; Sacchettini, J. C. Structure-guided discovery of phenyl-diketo acids as potent inhibitors of M. tuberculosis malate synthase Chem. Biol. 2012, 19, 1556-1567 10.1016/j.chembiol.2012.09.018
97. Zhao, F.; Liu, N.; Zhan, P.; Liu, X. Repurposing of HDAC inhibitors toward anti-hepatitis C virus drug discovery: teaching an old dog new tricks Future Med. Chem. 2015, 7, 1367-1371 10.4155/fmc.15.76
98. Song, Y.; Lin, X.; Kang, D.; Li, X.; Zhan, P.; Liu, X.; Zhang, Q. Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent CDC25 inhibitor and promising anticancer drug candidate Eur. J. Med. Chem. 2014, 82, 293-307 10.1016/j.ejmech.2014.05.063
99. Kankanala, J.; Kirby, K. A.; Liu, F.; Miller, L.; Nagy, E.; Wilson, D. J.; Parniak, M. A.; Sarafianos, S. G.; Wang, Z. Design, synthesis, and biological evaluations of hydroxypyridonecarboxylic acids as inhibitors of HIV reverse transcriptase associated RNase H J. Med. Chem. 2016, 59, 5051-5062 10.1021/acs.jmedchem.6b00465
100. Vernekar, S. K.; Liu, Z.; Nagy, E.; Miller, L.; Kirby, K. A.; Wilson, D. J.; Kankanala, J.; Sarafianos, S. G.; Parniak, M. A.; Wang, Z. Design, synthesis, biochemical, and antiviral evaluations of C6 benzyl and C6 biarylmethyl substituted 2-hydroxylisoquinoline-1,3-diones: dual inhibition against HIV reverse transcriptase-associated RNase H and polymerase with antiviral activities J. Med. Chem. 2015, 58, 651-664 10.1021/jm501132s
101. Tang, J.; Liu, F.; Nagy, E.; Miller, L.; Kirby, K. A.; Wilson, D. J.; Wu, B.; Sarafianos, S. G.; Parniak, M. A.; Wang, Z. 3-Hydroxypyrimidine-2,4-diones as selective active site inhibitors of HIV reverse transcriptase-associated RNase H: Design, synthesis, and biochemical evaluations J. Med. Chem. 2016, 59, 2648-2659 10.1021/acs.jmedchem.5b01879
102. Wu, B.; Tang, J.; Wilson, D. J.; Huber, A. D.; Casey, M. C.; Ji, J.; Kankanala, J.; Xie, J.; Sarafianos, S. G.; Wang, Z. 3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H J. Med. Chem. 2016, 59, 6136-6148 10.1021/acs.jmedchem.6b00040
103. Martin, D. P.; Hann, Z. S.; Cohen, S. M. Metalloprotein-inhibitor binding: human carbonic anhydrase II as a model for probing metal-ligand interactions in a metalloprotein active site Inorg. Chem. 2013, 52, 12207-12215 10.1021/ic400295f
104. Zhan, P.; Itoh, Y.; Suzuki, T.; Liu, X. Strategies for the discovery of target-specific or isoform-selective modulators J. Med. Chem. 2015, 58, 7611-7633 10.1021/acs.jmedchem.5b00229
105. Song, Y.; Xu, H.; Chen, W.; Zhan, P.; Liu, X. 8-Hydroxyquinoline: a privileged structure with a broad-ranging pharmacological potential MedChemComm 2015, 6, 61-74 10.1039/C4MD00284A
106. Zhan, P.; Liu, X.; Li, Z.; Pannecouque, C.; De Clercq, E. Design strategies of novel NNRTIs to overcome drug resistance Curr. Med. Chem. 2009, 16, 3903-3917 10.2174/092986709789178019
107. Zhan, P.; Song, Y.; Itoh, Y.; Suzuki, T.; Liu, X. Recent advances in the structure-based rational design of TNKSIs Mol. BioSyst. 2014, 10, 2783-2799 10.1039/C4MB00385C
108. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890 10.1038/nrd2445
109. Li, X.; Zhang, L.; Tian, Y.; Song, Y.; Zhan, P.; Liu, X. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011-2014) Expert Opin. Ther. Pat. 2014, 24, 1199-1227 10.1517/13543776.2014.964685